Skip to main content

Table 2 Changes in outcome measures (week 0 vs. week 1, week 0 vs. week 5) after treatment completion in patients who received Dangguixu-san or placebo for acute lateral ankle sprain (n = 23 each)

From: Effects of Dangguixu-san in patients with acute lateral ankle sprain: a randomized controlled trial

Groups Dependent variables Week 0 (M ± SD) Week 1 (M ± SD) Week 5 (M ± SD) Difference (w1–w0) Z (P)a Difference (w5–w0) Z (P)a x2 (P)b
DS group (n = 23) Degree of edema 0.67 ± 0.89 0.23 ± 0.43 0.21 ± 0.33 − 0.44 ± 0.93 − 2.57 (0.010) − 0.45 ± 0.83 − 2.47 (0.014) 6.48
(0.039)
VAS of pain 44.87 ± 17.02 24.96 ± 18.27 12.74 ± 16.20 − 19.91 ± 21.62 − 3.09 (0.002) − 32.13 ± 23.65 −3.75 (< 0.001) 32.89
(< 0.001)
TOTAL EQ-5D-5L 10.48 ± 3.06 8.35 ± 2.85 6.70 ± 2.77 −2.13 ± 2.69 −3.04 (0.002) −3.78 ± 4.22 − 3.49 (< 0.001) 26.42
(< 0.001)
TOTAL FAOS 307.43 ± 82.19 368.55 ± 74.72 430.09 ± 79.82 61.13 ± 72.52 −3.13 (0.002) 122.66
±107.34
−3.65 (< 0.001) 24.02
(< 0.001)
Placebo group (n = 23) Degree of edema 0.52 ± 0.67 0.27 ± 0.54 0.12 ± 0.44 −0.24 ± 0.53 −2.11 (0.035) −0.40 ± 0.70 −2.60 (0.009) 8.03
(0.018)
VAS of pain 44.04 ± 16.49 19.26 ± 14.14 14.87 ± 12.82 −24.78 ± 12.83 −4.07(< 0.001) − 29.17 ± 16.26 −3.94 (< 0.001) 36.56
(< 0.001)
TOTAL EQ-5D-5L 10.17 ± 2.61 7.61 ± 1.83 6.65 ± 1.70 −2.57 ± 1.78 −3.94(< 0.001) − 3.52 ± 2.84 − 3.72 (< 0.001) 32.84
(< 0.001)
TOTAL FAOS 299.54 ± 76.45 383.45 ± 66.80 428.00 ± 59.18 83.91 ± 74.37 −3.68(< 0.001) 128.46 ± 85.78 −3.83 (< 0.001) 28.17
(< 0.001)
  1. aWilcoxon signed-rank test; bRepeated measures ANOVA (Friedman test)